Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
This study showed that fenofibrate was very effective in lowering total, LDL, non-HDL cholesterol significantly in female diabetic patients compared to male patients….
Read More »Painful Diabetic Peripheral Neuropathy Patients Treated Successfully with Spinal Cord Stimulation
A clinical trial showed that SCS provided pain relief in patients with PDPN….
Read More »LX4211 Improved Glucose Control without Dose-Increasing Glucosuria in Type 2 Diabetes
In patients with type 2 diabetes, LX4211 produced greater dose-ranging effects on HbA1c than on glucosuria….
Read More »Diabetic Coronary Atherosclerosis Regression Seen with High-Intensity Statin Therapy
High-intensity statin therapy altered the progressive nature of coronary atheroma in diabetic and nondiabetic patients….
Read More »Childhood TV Viewing Habits Carry Over to Adulthood
A long-term British study revealed that there are correlations between childhood TV viewing time and adult TV viewing time….
Read More »The Effectiveness of Different Diet Programs on Weight Loss
Weight loss outcomes are comparable among named diet programs….
Read More »Vagal Nerve Blockade for Obesity Treatment
Vagal nerve blockade might not be an effective therapy for obesity treatment….
Read More »Overall Dietary Quality in the U.S Remains Poor
Better dietary quality links to higher socioeconomic status….
Read More »Afrezza – Dreamboat Inhaler and Cartridge
With this week’s Homerun Slides, we have a short special presentation for you on the new inhaled insulin, Afrezza, that goes with our exclusive interview by our publisher, Steve Freed, with the founder and CEO of Mannkind Corp, Al Mann….
Read More »An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
This week, we are taking a break from our Clinical Text presentations, to bring you this exclusive interview with Al Mann, the legendary founder of Mannkind Corp, and the person primarily responsible for backing the development of the inhaled insulin product, Afrezza, soon to be on the market. Steve Freed: …
Read More »